Ipilimumab

ایپیلیموماب

⚠ Unverified

🎗️ Antineoplastic And Immunomodulating AgentsCTLA-4 blocking antibody

Market / country: 🇺🇸 USA

Yervoy (US)

🧮 Dose calculator

Melanoma · Regimen source: FDA Yervoy · 2.2

  • • Only under an oncologist; continue until progression or unacceptable toxicity. Dose adjustments for toxicity and interactions per label. FDA Yervoy · 2.2
  • • Combinations with nivolumab and other indications (renal, colorectal, liver, lung, mesothelioma): different dose and interval per section 2. FDA Yervoy · 2

Enter age and weight.

🛡️ Safety & information

Warnings

  • • Severe and fatal immune-mediated reactions (pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, skin); infusion reactions; complications of allogeneic HSCT; embryo-fetal toxicity. FDA Yervoy · 5

Formulations

  • 5 mg/mL (50 mg/10 mL, 200 mg/40 mL) — injection 🇺🇸 USA FDA Yervoy · 3

👥 Special populations

  • 🤰 PregnancyDangerous / avoid

    Label: can cause fetal harm. Dangerous in pregnancy. FDA Yervoy · 8.1

    “Risk Summary Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology (12.1) ] , YERVOY can cause fetal harm when administered to a pregnant woman.”
  • 🤱 BreastfeedingDangerous / avoid

    Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Yervoy · 8.2

    “Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with YERVOY and for 3 months following the last dose.”
  • 👶 ChildrenUse with caution

    The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Yervoy · 8.4

    “The safety and effectiveness of YERVOY have been established in pediatric patients aged 12 years and older for the following indications: as a single agent and in combination with nivolumab for unresectable or metastatic melanoma, in combination with nivolumab for the treatment of MSI-H or dMMR unresectable and …”
  • 👴 Older adultsNo specific problem stated

    Label: no specific difference or dose adjustment stated for older adults. FDA Yervoy · 8.5

    “No overall differences in safety or effectiveness were observed between these patients and younger patients.”
  • ⚥ Females & males of reproductive potentialUse with caution

    Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Yervoy · 8.3

    “Contraception YERVOY can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] .”

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

🔗 Similar drugs

For the same diseases

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Information on this site is compiled from online websites and references. Doz accepts no responsibility for self-medication without approval from a physician and a reliable reference, or for any consequences of using this information.

Inspired by the Saphira project; part of the content is taken from it.

For suggestions, corrections, adding drugs or anything else, you can contact me on Telegram: @cenaav